Purple Biotech Operating Income 2014-2021 | PPBT

Purple Biotech operating income from 2014 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Purple Biotech Annual Operating Income
(Millions of US $)
2020 $-13
2019 $-7
2018 $-8
2017 $-12
2016 $-7
2015 $-4
2014 $-5
2013 $-3
Purple Biotech Quarterly Operating Income
(Millions of US $)
2021-06-30
2021-03-31 $-7
2020-12-31
2020-06-30
2019-12-31
2019-06-30
2018-12-31
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2015-12-31
2014-12-31
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.124B $0.001B
Purple Biotech Ltd. is a clinical-stage company focusing on therapies to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219 and CM24. Purple Biotech Ltd., formerly known as Kitov Pharma Ltd., is based in TEL AVIV, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29